体外肺モデルの世界市場：タイプ別、用途別、エンドユーザー別、地域別

世界の体外肺モデル市場は、2025年に3億3,800万米ドルと推定され、2032年までに8億6,660万米ドルに達すると予測され、2025年から2032年までのCAGRは14.4%で成長する見込みです。

図.体外肺モデルの世界市場シェア（%）、2025年地域別

体外肺モデルは、ヒト肺の生理学的・解剖学的特性を模倣することを目的とした実験システムです。創薬、毒性試験、肺疾患の研究に広く利用されています。体外で培養したヒト肺細胞や組織を利用することで、これらのモデルは動物実験に代わる比較的安価で効果的な代替手段を提供します。また、動物モデルと比較して、より現実的で制御可能な環境を提供し、ヒト肺の生物学や疾患病態を研究することができます。今後、組織工学、マイクロ流体工学、その他の技術の進歩により、生体内の肺微小環境をよりよく再現できる高度に複雑な3D肺モデルの開発に役立つことが期待されます。

市場力学：

世界の体外肺モデル市場は、製薬会社による医薬品研究開発投資の増加、動物実験に関する厳しい規制、呼吸器疾患の有病率の増加などの要因によって牽引されています。しかし、高度な3D肺モデルの開発に伴う高コストや組織の保存期間の短さが、市場の成長を抑制すると予想されます。一方、微細加工技術や3Dバイオプリンティング技術の開発が進んでいることから、次世代バイオミメティックモデルを開発する大きな機会が生まれると予測されます。また、個々の患者由来の細胞や組織を組み込んだパーソナライズド肺モデルの開発に注目が集まっていることから、市場の拡大が見込まれます。

一方、市場参入企業による研究開発の高まりは、予測期間中の市場成長をさらに促進すると予想されます。例えば、2024年3月6日、バイオテクノロジー企業のAlveoliX AG社は、Frontiers Media S.A.に研究を発表した、喘息、慢性閉塞性肺疾患（COPD）、線維症などの様々な呼吸器疾患に対して、米国食品医薬品局（FDA）が開発した薬剤の数が限られているため、「A multiplex inhalation platform to model in situ like aerosol delivery in a breathing lung-on-chip」と題した研究を発表しました。これらの深刻な肺疾患に対して米国食品医薬品局（FDA）が承認した吸入薬剤の数は限られているため、前臨床研究において吸入粒子の毒性をより正確に予測するために、生体内から代替の生体外ヒト関連モデルの使用へとシフトしています。

この研究の主な特徴

• この調査レポートは、世界の試験管内肺モデル市場を詳細に分析し、2024年を基準年とした予測期間（2025年～2032年）の市場規模および複合年間成長率（CAGR%）を掲載しています。
• また、さまざまなセグメントにわたる潜在的な収益機会を解明し、この市場の魅力的な投資提案マトリクスを解説しています。
• また、市場促進要因、抑制要因、機会、新製品の上市や承認、市場動向、地域別の展望、主要企業が採用する競争戦略などに関する重要な考察も提供しています。
• 企業ハイライト、製品ポートフォリオ、主要なハイライト、業績、戦略などのパラメータに基づいて、世界の体外肺モデル市場の主要企業プロファイルを掲載しています。
• このレポートからの洞察は、マーケティング担当者や企業の経営陣が、将来の製品の発売、タイプのアップグレード、市場拡大、マーケティング戦術に関する情報に基づいた意思決定を行うことを可能にします。
• 世界の体外肺モデル市場レポートは、投資家、サプライヤー、製品メーカー、流通業者、新規参入者、財務アナリストなど、この業界のさまざまな利害関係者を対象としています。
• 利害関係者は、世界の体外肺モデル市場の分析に使用される様々な戦略マトリックスを通じて、意思決定が容易になります。

目次

第1章 調査の目的と前提条件

• 調査目的
• 前提条件
• 略語

第2章 市場の展望

• レポートの説明
  • 市場の定義と範囲
• エグゼクティブサマリー
• Coherent Opportunity Map（COM）

第3章 市場力学、規制、動向分析

• 市場力学
• 影響分析
• 主なハイライト
• 規制シナリオ
• サービス提供ポートフォリオ
• PEST分析
• PORTERの分析
• 合併と買収のシナリオ

第4章 世界の体外肺モデル市場- コロナウイルス（COVID-19）パンデミックの影響

• COVID-19疫学
• 供給側と需要側の分析
• 経済への影響

第5章 世界の体外肺モデル市場、タイプ別、2020年～2032年

• 2Dモデル
• 3Dモデル

第6章 世界の体外肺モデル市場、用途別、2020-2032年

• 創薬と毒性学研究
• 生理学的調査
• 3Dモデル開発
• その他

第7章 世界の体外肺モデル市場、エンドユーザー別、2020年～2032年

• 学術調査機関
• バイオ医薬品企業
• その他

第8章 世界の体外肺モデル市場、地域別、2020年～2032年

• 北米
• 欧州
• アジア太平洋
• ラテンアメリカ
• 中東
• アフリカ

第9章 競合情勢

• Epithelix
• MATTEK
• Lonza
• Emulate
• AlveoliX AG
• Nortis
• CN Bio Innovations Ltd
• MIMETAS
• InSphero
• ATTC Global
• Tissuse GmbH
• Cn Bio Innovations Limited

第10章 セクション

• 調査手法
• 出版社について

Global In Vitro Lung Model Market is estimated to be valued at USD 338.0 Mn in 2025 and is expected to reach USD 866.6 Mn by 2032, growing at a compound annual growth rate (CAGR) of 14.4% from 2025 to 2032.

Figure. Global In Vitro Lung Model Market Share (%), By Region 2025

In vitro lung models are experimental systems that aim to mimic the physiological and anatomical properties of the human lungs. They are widely used in drug discovery, toxicity testing, and studying lung diseases. By utilizing human lung cells and tissues grown outside of the body, these models offer a relatively affordable and effective alternative to animal testing. They also provide a more realistic and controllable environment to study human lung biology and disease pathology compared to animal models. Going forward, advances in tissue engineering, microfluidics, and other technologies are expected to help develop highly complex 3D lung models that can better recreate the in vivo lung microenvironment.

Market Dynamics:

The global in vitro lung model market is driven by factors such as rising drug R&D investments by pharmaceutical companies, stringent regulations regarding animal testing, and increasing prevalence of respiratory diseases. However, high costs associated with developing advanced 3D lung models and shorter shelf life of tissues are expected to restrain the market growth. Meanwhile, ongoing advances in microfabrication and 3D bioprinting technologies are projected to create significant opportunities for manufacturers to develop next-gen biomimetic models. The market is also anticipated to gain from growing focus on developing personalized lung models incorporating individual patient-derived cells and tissues.

On the other hand, rising research and development by market players is further expected to propel the market growth over the forecast period. For instance, on March 6, 2024, AlveoliX AG, a biotechnology company, published a study in Frontiers Media S.A., a peer-reviewed, open access, scientific journals, entitled "A multiplex inhalation platform to model in situ like aerosol delivery in a breathing lung-on-chip" for various respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD) and fibrosis, due to limited number of U.S. Food and Drug Administration, approved inhaled drugs for these serious lung conditions has led to a shift from in vivo towards the use of alternative in vitro human-relevant models to better predict the toxicity of inhaled particles in preclinical research.

Key features of the study:

• This report provides an in-depth analysis of the global In vitro lung model market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global In vitro lung model market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Histogen Inc., OliX Pharmaceuticals, Cipla Limited, Aclaris Therapeutics, Inc., Merck & Co., Inc., Daiichi-Sankyo Co., Ltd., Johnson and Johnson Services, Inc., Lexington International LLC, Vita-Cos-Med Klett-Loch GmbH, PureTech, Vitabiotics, Dr. Reddy's Laboratories, HCell Inc., Follica, Inc. and Ranbaxy Laboratories Ltd.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global In vitro lung model market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global In vitro lung model market

Detailed Segmentation:

• Global In Vitro Lung Model Market, By Type
  • 2D Model
  • 3D Model
• Global In Vitro Lung Model Market, By Application
  • Drug Discovery & Toxicology Studies
  • Physiological Research
  • 3D Model Development
  • Others
• Global In Vitro Lung Model Market, By End User
  • Academic and Research Institutes
  • Biopharmaceutical Companies
  • Others
• Global In Vitro Lung Model Market, By Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa
• Company Profiles
  • Histogen Inc.
  • OliX Pharmaceuticals
  • Cipla Limited
  • Aclaris Therapeutics, Inc.
  • Merck & Co., Inc.
  • Daiichi-Sankyo Co., Ltd.
  • Johnson and Johnson Services, Inc.
  • Lexington International LLC
  • Vita-Cos-Med Klett-Loch GmbH
  • PureTech
  • Vitabiotics
  • Dr. Reddy's Laboratories
  • HCell Inc.
  • Follica, Inc.
  • Ranbaxy Laboratories Ltd.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Global In Vitro Lung Model Market, By Type
  • Global In Vitro Lung Model Market, By Application
  • Global In Vitro Lung Model Market, By End User
  • Global In Vitro Lung Model Market, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Rising prevalence of lung diseases
  • High costs associated with animal models
  • Growing preference for 3D lung models over 2D models
• Impact Analysis
• Key Highlights
• Regulatory Scenario
• Service offering Portfolio
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario

4. Global In Vitro Lung Model Market- Impact of Coronavirus (COVID-19) Pandemic

• COVID-19 Epidemiology
• Supply Side and Demand Side Analysis
• Economic Impact

5. Global In Vitro Lung Model Market, By Type, 2020-2032, (US$ Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• 2D Model
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
• 3D Model
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)

6. Global In Vitro Lung Model Market, By Application, 2020-2032, (US$ Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Drug Discovery & Toxicology Studies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
• Physiological Research
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
• 3D Model Development
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)

7. Global In Vitro Lung Model Market, By End User, 2020-2032, (US$ Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Academic and Research Institutes
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
• Biopharmaceutical Companies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)

8. Global In Vitro Lung Model Market, By Region, 2020-2032, (US$ Mn)

• Introduction
  • Market Share Analysis, By Country, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, For Country 2021 -2032
  • Country Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Mn)
    • U.S.
    • Canada
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Mn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Mn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Mn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Mn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020-2032, (US$ Mn)
    • North Africa
    • Central Africa
    • South Africa

9. Competitive Landscape

• Epithelix
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• MATTEK
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Lonza
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Emulate
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• AlveoliX AG
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Nortis
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
  • Strategies
• CN Bio Innovations Ltd
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• MIMETAS
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• InSphero
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• ATTC Global
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Tissuse GmbH
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Cn Bio Innovations Limited
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Analyst Views

10. Section

• Research Methodology
• About us